🇺🇸 FDA
Company

Aptose

Aptose Biosciences

APTOF biotech USA

Quick answer

Aptose is a biotech company (APTOF) headquartered in TORONTO, USA with 8 tracked pipeline programs.

Pipeline (8)

project

Virulizin®

Pancreatic Cancer

Phase 3 · small_molecule · completed

1 trials project

GTI-2040

Carcinoma, Renal Cell

Phase 2 · small_molecule · completed

1 trials project

GTI-2040

Acute Myeloid Leukemia

Phase 2 · mab · completed

1 trials project

Tuspetinib

Leukemia, Myeloid, Acute

Phase 2 · small_molecule · active

1 trials project

APTO-253

Acute Myelogenous Leukemia in Relapse

Phase 1 · small_molecule · terminated

1 trials project

CG-806

Acute Myeloid Leukemia

Phase 1 · small_molecule · terminated

1 trials project

CG-806

Chronic Lymphocytic Leukemia

Phase 1 · small_molecule · terminated

1 trials project

LOR-253 HCl

Advanced or Metastatic Solid Tumours

Phase 1 · small_molecule · completed

1 trials

Patents (7)

patent

US 11279703

Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use

Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11149047

Aryl imidazoles for treatment of cancer

Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11104957

Compositions and methods for treating cancers

Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10080739

Aryl imidazoles and their use as anti-cancer agents

Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9567643

Compositions and methods for treating cancers

Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 8987305

2,4,5-trisubstituted imidazoles and their use as anti-microbial agents

Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 8969372

Aryl imidazoles and their use as anti-cancer agents

Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)